Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-0520 in EGFR Inhibitor-induced Folliculitis
NCT06818058Phase 2Recruiting
- Sponsor
- Tarian Pharma
- Start
- Jan 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Onreltea in folliculitis (2 arms), sponsored by Tarian Pharma. Primary endpoint: Frequency of Treatment-emergent Adverse Events at Day 56. Started Jan 2025; status: recruiting.
02
Drugs
Onreltea
03
Conditions
folliculitis
Beyond the preview
Go deeper on NCT06818058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818058.